Electrolyte Disturbances

Bloodless Hyperkalemia Test Gets FDA's Breakthrough Device Designation

By September 12, 2018

The KardiaK Platform works through a deep neural network trained to detect hyperkalemia based on data from electrocardiograms (ECG) similar to those captured by the Company's KardiaMobile and KardiaBand devices.

FDA Approves First Drug Under the Competitive Generic Therapy Pathway

By August 08, 2018

Potassium chloride is an oral treatment indicated for the treatment and prevention of hypokalemia (low potassium blood levels) in patients who are on diuretics, and when dietary management with potassium-rich foods is insufficient or diuretic dose reduction is not possible.

Positive Results Announced for First-in-Class Metabolic Acidosis Treatment

By June 05, 2018

After 12 weeks, 59.2% of patients treated with the study drug saw an increased blood bicarbonate of ≥4mEq/L or achieved a level in the normal range (22 to 29mEq/L) vs 22.5% of patients in the placebo group (primary endpoint; P <.0001).

Hyperkalemia Treatment Lokelma Gets FDA Approval

By May 21, 2018

Lokelma is a non-absorbed zirconium silicate that preferentially captures potassium in exchange for hydrogen and sodium.

Veltassa Approval Allows for More Dosing Flexibility for Hyperkalemia

By May 08, 2018

The approval was based on data from the Phase 4 TOURMALINE trial which randomized 114 patients with hyperkalemia to receive Valtessa once daily with food or without food for 4 weeks

Klor-Con Powder for Oral Solution Now Available

By November 28, 2017

Klor-Con Powder for oral solution is available as packets that contain 1.5g of potassium chloride (supplying potassium 20mEq and chloride 20mEq) in 30- and 100-count cartons.

Patient Experiences Severe Paralysis After Trigger-Point Injection Therapy

By June 22, 2017

Initially, the patient experienced no complications. But approximately 12 hours following therapy, he awoke with shortness of breath and functional quadriplegia.

Boxed Warning Removed for Hyperkalemia Treatment

By November 28, 2016

The Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) updating the label for Veltassa (patiromer; Relypsa) for oral suspension.

Ure-Na Launched for Hyponatremia Management

By June 08, 2016

Nephcentric announced the launch of Ure-Na (urea), a new medical food for the management of euvolemic and hypervolemic hyponatremia, including syndrome of inappropriate ADH secretion (SIADH).

Hospira Recalls Magnesium Sulfate Injection

By April 14, 2016

Hospira announced a voluntary recall of one lot of 50% Magnesium Sulfate Injection, 10g/20mL (0.5/gmL), 20mL single-dose vials.

Sodium Bicarb Injection Recalled Due to Particulate Presence

By March 21, 2016

Hospira announced a voluntary recall of one lot of Sodium Bicarbonate Injection 8.4%, USP, due to particulate presence within a single-dose glass fliptop vial from a confirmed complaint.

Hyponatremia a Serious Risk to Ironman Competitors

March 11, 2016

Long-distance triathletes who drink too much water during competition may end up with hyponatremia, according to a letter to the editor published in the March 10 issue of the New England Journal of Medicine.

Vaprisol Inj Effectively Increases Serum Sodium in Multicenter Study

By February 10, 2016

Cumberland announced the publication of data from a multicenter, open-label study that further supports the use of Vaprisol (conivaptan) Injection.

Lupin Approved for Potassium Chloride Extended Release Caps

By January 19, 2016

Lupin announced that it has received final approval from the Food and Drug Administration (FDA) for its Potassium Chloride Extended Release Capsules, a generic version of Actavis' Potassium Chloride Extended Release Capsules.

Insect Presence Found in IV Electrolytes, Hydration Products

By January 05, 2016

Baxter announced a voluntary recall of 2 lots of 0.9% Sodium Chloride Injection, 250mL Viaflex Plastic Container and 70% Dextrose Injection, 2000mL, due to potential presence of particulate matter.

Unit Dose Version of KCl Solution Launched

By December 14, 2015

VistaPharm announced the launch of Potassium Chloride Solution, 10% in Unit Dose. The unit dose version of the only approved Potassium Chloride oral solution.

Veltassa Approved for Hyperkalemia

By October 22, 2015

Relypsa announced that the Food and Drug Administration (FDA) has approved Veltassa (patiromer) for oral suspension, indicated for the treatment of hyperkalemia.

Insect Discovery in IV Solution Bags Prompts Recall

By July 20, 2015

Baxter announced a voluntary recall of two lots of 0.9% Sodium Chloride intravenous (IV) solutions due to potential particulate matter.

Novel Oral Susp Found Effective in Treating Hyperkalemia

By July 14, 2015

Patiromer oral suspension, an investigational drug, was found to reduce elevated potassium levels in patients with chronic diabetic kidney disease in a study published in JAMA.

Mold Discovered in Lactated Ringer's Solution

By March 12, 2015

Hospira has announced a voluntary recall of one lot of Lactated Ringer's Irrigation 3000mL following a confirmed customer report of several dark, fibrous particulate floating within the solution of the primary container.

Human Hair Found in Sodium Chloride Injection

By January 23, 2015

Hospira announced a voluntary recall of one lot of 0.9% Sodium Chloride Injection due to particulate matter sealed in the bag at the additive port area. The particulate matter was identified as a human hair.

Phoxillum Approved for Electrolyte Imbalances in CRRT

By January 20, 2015

Baxter announced that the Food and Drug Administration (FDA) has approved Phoxillum Renal Replacement Solutions (BK4/2.5 and B2K4/0) for use in continuous renal replacement therapy (CRRT) to replace plasma volume removed by ultrafiltration, correct electrolyte and acid-base imbalances, and for use in drug poisoning when CRRT is used to remove dialyzable substances.

Two Agents Show Promise for Hyperkalemia

November 24, 2014

For patients with hyperkalemia, sodium zirconium cyclosilicate (ZS-9) and patiromer show promise for reducing potassium levels, according to two new studies.

Mislabeling Leads to Recall of Highly Concentrated Potassium Chloride

November 21, 2014

Baxter announced a voluntary recall of one lot of Highly Concentrated Potassium Chloride Injection 10mEq/100mL at the user level due to a complaint of mislabeling of the overpouch.

Which Antidepressants Are Linked to Greater Hyponatremia Risk?

September 05, 2014

Hyponatremia can be a potentially dangerous side effect of certain antidepressant medications based on antidepressant class.

Mylan Launches Generic Klor-Con Tablets

August 22, 2014

Mylan announced its launch of Potassium Chloride Extended-Release Tablets, the generic version of Upsher-Smith's Klor-Con.

Fluid Restrictions May Cut Post-Op Complications in Pancreaticoduodenectomy

August 20, 2014

For patients undergoing pancreaticoduodenectomy (PD), fluid restrictions with 3% hypertonic saline can significantly cut complication rates.

New Flexbumin 5% Strength Approved

August 04, 2014

Baxter announced that the FDA has approved Flexbumin (albumin [human]) 5% solution for the treatment of hypovolemia, hypoalbuminemia due to general causes, burns, and for use during cardiopulmonary bypass surgery as a component of the pump prime.

Lactated Ringers and 5% Dextrose Inj Found to Contain Mold

July 11, 2014

Hospira announced a voluntary nationwide recall of one lot of Lactated Ringers and 5% Dextrose Injection, USP, 1000mL, Flexible Container.

Rx Adherence Up for Hispanics Post-Medicare Part D Launch

June 04, 2014

Hispanics became much more likely to take their heart medicines after Medicare's prescription drug benefit plan was launched in 2006, but there was only a small increase seen among black patients.